Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 549Carcinoma, Non-Small-Cell Lung 509Prostatic Neoplasms 333Colorectal Neoplasms 270Multiple Myeloma 266Neoplasms 262Leukemia, Myeloid, Acute 221Squamous Cell Carcinoma of Head and Neck 214Lung Neoplasms 207Neoplasm Metastasis 203Carcinoma, Hepatocellular 197Melanoma 172Triple Negative Breast Neoplasms 171Pancreatic Neoplasms 170Recurrence 152Ovarian Neoplasms 149Lymphoma 139Brain Neoplasms 133Glioblastoma 132Sarcoma 130Carcinoma, Renal Cell 126Leukemia, Lymphocytic, Chronic, B-Cell 125Head and Neck Neoplasms 124Stomach Neoplasms 122Lymphoma, Large B-Cell, Diffuse 122Rectal Neoplasms 107Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Myelodysplastic Syndromes 102Uterine Cervical Neoplasms 100Urinary Bladder Neoplasms 100

Interventions

testosterone enanthate 1testosterone 17 beta-cypionate 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Castration Resistant Metastatic Prostate Cancer × 1 year × Clear all
NCT04363164 2026-04-06

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
150 enrolled
Genitourinary

Castration Resistant Metastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡